Dionysios Th Dimas1, Christina D Perlepe1,2, Theodoros N Sergentanis3, Ioannis Misitzis4, Konstantinos Kontzoglou5, Efstratios Patsouris6, Gregory Kouraklis5, Theodora Psaltopoulou2, Afroditi Nonni6. 1. Department of Surgery, "Elpis" General Hospital of Athens, Athens, Greece. 2. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National University of Athens, Athens, Greece. 3. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National University of Athens, Athens, Greece tsergentanis@yahoo.gr. 4. Breast Cancer Surgical Department, "Ag. Savvas" Anticancer Hospital, Athens, Greece. 5. Second Department of Propedeutic Surgery, Medical School, University of Athens, "Laikon" General Hospital, Athens, Greece. 6. First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Abstract
BACKGROUND/AIM: Studies have focused on heat shock protein (Hsp) inhibitors as potential treatment agents in breast cancer, with controversial results. Adopting a pathophysiological perspective, this systematic review aims to synthesize the evidence examining the association between Hsp70/Hsp90 expression and breast cancer prognosis, as well as prognosis-related clinicopathological indices. Secondarily, changes in Hsp70/Hsp90 expression in the continuum of breast neoplasia were assessed. MATERIALS AND METHODS: Hsp70/Hsp90 expression was approached globally, quantified by means of immunohistochemistry, western blot or PCR. This study was performed in accordance with the PRISMA guidelines. Relevant studies were sought in PubMed, up to December 31, 2015. RESULTS: A total of 23 eligible studies were identified (7,288 breast cancer cases). High Hsp90 expre s sion was associated with worse overall survival (pooled RR=1.48, 95%CI=1.21-1.82) and marginally with worse disease-free survival. High Hsp70 expression also correlated with worse disease-free survival (pooled RR=1.77, 95%CI=1.71-2.82). Hsp70 intense expression correlated with ER positivity (pooled OR=3.51, 95%CI=1.31-9.40) and PR positivity (pooled OR=2.48, 95%CI=1.39-4.44). No significant associations were noted between Hsp70/Hsp90 expression and clinicopathological variables including histological grade, tumor size, nodal metastasis or patient age at diagnosis. No clear pattern emerged for Hsp70/Hsp90 expression along the breast neoplasia continuum. CONCLUSION: This systematic review and meta-analysis highlights the prognostic role of Hsp90 and Hsp70 expression in breast cancer. Further high-quality studies, with detailed reporting are needed to provide epidemiological evidence complementing the findings of ongoing clinical trials on Hsp inhibitors. Copyright
BACKGROUND/AIM: Studies have focused on heat shock protein (Hsp) inhibitors as potential treatment agents in breast cancer, with controversial results. Adopting a pathophysiological perspective, this systematic review aims to synthesize the evidence examining the association between Hsp70/Hsp90 expression and breast cancer prognosis, as well as prognosis-related clinicopathological indices. Secondarily, changes in Hsp70/Hsp90 expression in the continuum of breast neoplasia were assessed. MATERIALS AND METHODS:Hsp70/Hsp90 expression was approached globally, quantified by means of immunohistochemistry, western blot or PCR. This study was performed in accordance with the PRISMA guidelines. Relevant studies were sought in PubMed, up to December 31, 2015. RESULTS: A total of 23 eligible studies were identified (7,288 breast cancer cases). High Hsp90 expre s sion was associated with worse overall survival (pooled RR=1.48, 95%CI=1.21-1.82) and marginally with worse disease-free survival. High Hsp70 expression also correlated with worse disease-free survival (pooled RR=1.77, 95%CI=1.71-2.82). Hsp70 intense expression correlated with ER positivity (pooled OR=3.51, 95%CI=1.31-9.40) and PR positivity (pooled OR=2.48, 95%CI=1.39-4.44). No significant associations were noted between Hsp70/Hsp90 expression and clinicopathological variables including histological grade, tumor size, nodal metastasis or patient age at diagnosis. No clear pattern emerged for Hsp70/Hsp90 expression along the breast neoplasia continuum. CONCLUSION: This systematic review and meta-analysis highlights the prognostic role of Hsp90 and Hsp70 expression in breast cancer. Further high-quality studies, with detailed reporting are needed to provide epidemiological evidence complementing the findings of ongoing clinical trials on Hsp inhibitors. Copyright
Authors: Lucía Zhu; Diana Retana; Pedro García-Gómez; Laura Álvaro-Espinosa; Neibla Priego; Mariam Masmudi-Martín; Natalia Yebra; Lauritz Miarka; Elena Hernández-Encinas; Carmen Blanco-Aparicio; Sonia Martínez; Cecilia Sobrino; Nuria Ajenjo; Maria-Jesus Artiga; Eva Ortega-Paino; Raúl Torres-Ruiz; Sandra Rodríguez-Perales; Riccardo Soffietti; Luca Bertero; Paola Cassoni; Tobias Weiss; Javier Muñoz; Juan Manuel Sepúlveda; Pedro González-León; Luis Jiménez-Roldán; Luis Miguel Moreno; Olga Esteban; Ángel Pérez-Núñez; Aurelio Hernández-Laín; Oscar Toldos; Yolanda Ruano; Lucía Alcázar; Guillermo Blasco; José Fernández-Alén; Eduardo Caleiras; Miguel Lafarga; Diego Megías; Osvaldo Graña-Castro; Carolina Nör; Michael D Taylor; Leonie S Young; Damir Varešlija; Nicola Cosgrove; Fergus J Couch; Lorena Cussó; Manuel Desco; Silvana Mouron; Miguel Quintela-Fandino; Michael Weller; Joaquín Pastor; Manuel Valiente Journal: EMBO Mol Med Date: 2022-02-17 Impact factor: 12.137
Authors: Tobias Hofving; Viktor Sandblom; Yvonne Arvidsson; Emman Shubbar; Gülay Altiparmak; John Swanpalmer; Bilal Almobarak; Anna-Karin Elf; Viktor Johanson; Erik Elias; Erik Kristiansson; Eva Forssell-Aronsson; Ola Nilsson Journal: Endocr Relat Cancer Date: 2019-02-01 Impact factor: 5.678
Authors: Kensuke Kaneko; Takuya Osada; Michael A Morse; William R Gwin; Joshua D Ginzel; Joshua C Snyder; Xiao-Yi Yang; Cong-Xiao Liu; Márcio A Diniz; Khaldon Bodoor; Philip F Hughes; Timothy Aj Haystead; H Kim Lyerly Journal: Commun Biol Date: 2020-05-08